Zimmer Biomet Holdings, Inc. (ZBH)
USD 105.86
(-2.04%)
USD 105.86
(-2.04%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.57 Billion USD | 4.86% |
| 2022 | 5.32 Billion USD | -20.6% |
| 2021 | 6.7 Billion USD | -8.51% |
| 2020 | 7.32 Billion USD | -3.67% |
| 2019 | 7.6 Billion USD | -9.44% |
| 2018 | 8.39 Billion USD | -12.71% |
| 2017 | 9.61 Billion USD | -9.36% |
| 2016 | 10.61 Billion USD | 5.02% |
| 2015 | 10.1 Billion USD | 2852.57% |
| 2014 | 342.2 Million USD | -42.22% |
| 2013 | 592.2 Million USD | -36.77% |
| 2012 | 936.6 Million USD | -1.51% |
| 2011 | 951 Million USD | 100.97% |
| 2010 | 473.2 Million USD | 8.56% |
| 2009 | 435.9 Million USD | 76.12% |
| 2008 | 247.5 Million USD | 168.83% |
| 2007 | -359.6 Million USD | -116.5% |
| 2006 | -166.1 Million USD | -9.56% |
| 2005 | -151.6 Million USD | -130.51% |
| 2004 | 496.9 Million USD | -51.83% |
| 2003 | 1.03 Billion USD | 631.63% |
| 2002 | 141 Million USD | -59.19% |
| 2001 | 345.5 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 5.4 Billion USD | -3.16% |
| 2024 Q3 | 6 Billion USD | 10.88% |
| 2024 Q2 | 5.41 Billion USD | 0.21% |
| 2023 FY | 5.57 Billion USD | 4.86% |
| 2023 Q1 | 5.45 Billion USD | 2.61% |
| 2023 Q2 | 5.38 Billion USD | -1.28% |
| 2023 Q3 | 5.19 Billion USD | -3.7% |
| 2023 Q4 | 5.57 Billion USD | 7.5% |
| 2022 Q4 | 5.32 Billion USD | -0.52% |
| 2022 Q1 | 5.86 Billion USD | -12.48% |
| 2022 Q2 | 5.76 Billion USD | -1.7% |
| 2022 Q3 | 5.34 Billion USD | -7.22% |
| 2022 FY | 5.32 Billion USD | -20.6% |
| 2021 Q3 | 6.59 Billion USD | -3.16% |
| 2021 Q1 | 7.11 Billion USD | -2.87% |
| 2021 Q2 | 6.8 Billion USD | -4.3% |
| 2021 FY | 6.7 Billion USD | -8.51% |
| 2021 Q4 | 6.7 Billion USD | 1.63% |
| 2020 Q4 | 7.32 Billion USD | 0.07% |
| 2020 Q1 | 7.23 Billion USD | -4.85% |
| 2020 FY | 7.32 Billion USD | -3.67% |
| 2020 Q2 | 7.49 Billion USD | 3.6% |
| 2020 Q3 | 7.31 Billion USD | -2.36% |
| 2019 FY | 7.6 Billion USD | -9.44% |
| 2019 Q2 | 8.31 Billion USD | 1.12% |
| 2019 Q3 | 7.82 Billion USD | -5.91% |
| 2019 Q4 | 7.6 Billion USD | -2.83% |
| 2019 Q1 | 8.22 Billion USD | -1.88% |
| 2018 Q3 | 8.67 Billion USD | -3.78% |
| 2018 Q4 | 8.38 Billion USD | -3.36% |
| 2018 FY | 8.39 Billion USD | -12.71% |
| 2018 Q2 | 9.01 Billion USD | -3.57% |
| 2018 Q1 | 9.34 Billion USD | -2.82% |
| 2017 Q3 | 9.94 Billion USD | -2.83% |
| 2017 Q2 | 10.23 Billion USD | -2.29% |
| 2017 Q1 | 10.47 Billion USD | -1.3% |
| 2017 FY | 9.61 Billion USD | -9.36% |
| 2017 Q4 | 9.61 Billion USD | -3.28% |
| 2016 Q3 | 10.53 Billion USD | 10.19% |
| 2016 Q1 | 10.12 Billion USD | 0.5% |
| 2016 Q4 | 10.61 Billion USD | 0.76% |
| 2016 FY | 10.61 Billion USD | 5.02% |
| 2016 Q2 | 9.55 Billion USD | -5.57% |
| 2015 Q3 | 10.44 Billion USD | -1.67% |
| 2015 Q2 | 10.62 Billion USD | 3869.07% |
| 2015 Q1 | 267.7 Million USD | -15.87% |
| 2015 FY | 10.1 Billion USD | 2852.57% |
| 2015 Q4 | 10.07 Billion USD | -3.61% |
| 2014 Q1 | 797.4 Million USD | 34.65% |
| 2014 Q4 | 318.2 Million USD | -30.69% |
| 2014 Q2 | 718.7 Million USD | -9.87% |
| 2014 FY | 342.2 Million USD | -42.22% |
| 2014 Q3 | 459.1 Million USD | -36.12% |
| 2013 Q1 | 1.04 Billion USD | 15.85% |
| 2013 FY | 592.2 Million USD | -36.77% |
| 2013 Q4 | 592.2 Million USD | -22.95% |
| 2013 Q3 | 768.6 Million USD | -21.43% |
| 2013 Q2 | 978.2 Million USD | -6.46% |
| 2012 Q2 | 1.75 Billion USD | -0.11% |
| 2012 Q1 | 1.76 Billion USD | 85.13% |
| 2012 FY | 936.6 Million USD | -1.51% |
| 2012 Q4 | 902.7 Million USD | -46.53% |
| 2012 Q3 | 1.68 Billion USD | -4.01% |
| 2011 Q2 | 523.2 Million USD | -7.33% |
| 2011 Q3 | 990.5 Million USD | 89.32% |
| 2011 Q4 | 951 Million USD | -3.99% |
| 2011 FY | 951 Million USD | 100.97% |
| 2011 Q1 | 564.6 Million USD | 19.32% |
| 2010 Q4 | 473.2 Million USD | 115.09% |
| 2010 Q2 | 176.9 Million USD | -42.15% |
| 2010 FY | 473.2 Million USD | 8.56% |
| 2010 Q1 | 305.8 Million USD | -29.85% |
| 2010 Q3 | 220 Million USD | 24.36% |
| 2009 FY | 435.9 Million USD | 76.12% |
| 2009 Q4 | 435.9 Million USD | 171.59% |
| 2009 Q3 | 160.5 Million USD | -57.31% |
| 2009 Q2 | 376 Million USD | -16.0% |
| 2009 Q1 | 447.6 Million USD | 80.85% |
| 2008 FY | 247.5 Million USD | 168.83% |
| 2008 Q1 | -359.1 Million USD | 0.14% |
| 2008 Q2 | -58.8 Million USD | 83.63% |
| 2008 Q3 | -211.3 Million USD | -259.35% |
| 2008 Q4 | 247.5 Million USD | 217.13% |
| 2007 Q1 | -226 Million USD | -36.06% |
| 2007 Q4 | -359.6 Million USD | -71.4% |
| 2007 Q3 | -209.8 Million USD | 20.38% |
| 2007 Q2 | -263.5 Million USD | -16.59% |
| 2007 FY | -359.6 Million USD | -116.5% |
| 2006 FY | -166.1 Million USD | -9.56% |
| 2006 Q1 | -322.3 Million USD | -112.6% |
| 2006 Q2 | -253.2 Million USD | 21.44% |
| 2006 Q3 | -174.7 Million USD | 31.0% |
| 2006 Q4 | -166.1 Million USD | 4.92% |
| 2005 Q1 | 369.3 Million USD | -25.68% |
| 2005 FY | -151.6 Million USD | -130.51% |
| 2005 Q2 | 189.3 Million USD | -48.74% |
| 2005 Q3 | -6 Million USD | -103.17% |
| 2005 Q4 | -151.6 Million USD | -2426.67% |
| 2004 Q1 | 851 Million USD | -17.51% |
| 2004 Q4 | 496.9 Million USD | -21.76% |
| 2004 Q3 | 635.1 Million USD | -19.81% |
| 2004 Q2 | 792 Million USD | -6.93% |
| 2004 FY | 496.9 Million USD | -51.83% |
| 2003 FY | 1.03 Billion USD | 631.63% |
| 2003 Q1 | 43.5 Million USD | -69.15% |
| 2003 Q2 | -39 Million USD | -189.66% |
| 2003 Q3 | -97 Million USD | -148.72% |
| 2003 Q4 | 1.03 Billion USD | 1163.51% |
| 2002 Q3 | 228.1 Million USD | -20.36% |
| 2002 Q1 | 321.4 Million USD | -6.98% |
| 2002 Q2 | 286.4 Million USD | -10.89% |
| 2002 FY | 141 Million USD | -59.19% |
| 2002 Q4 | 141 Million USD | -38.19% |
| 2001 Q3 | 384.9 Million USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 FY | 345.5 Million USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q4 | 345.5 Million USD | -10.24% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott Laboratories | 8.97 Billion USD | 37.848% |
| Allurion Technologies Inc. | 3.82 Million USD | -145957.592% |
| Artivion, Inc. | 300.4 Million USD | -1757.317% |
| Avanos Medical, Inc. | 121.4 Million USD | -4495.881% |
| Butterfly Network, Inc. | -109.6 Million USD | 5190.275% |
| Butterfly Network, Inc. | -109.6 Million USD | 5190.275% |
| Bio-Rad Laboratories, Inc. | 1 Billion USD | -456.866% |
| Boston Scientific Corporation | 8.62 Billion USD | 35.326% |
| Perspective Therapeutics, Inc. | -20.99 Million USD | 26677.431% |
| CONMED Corporation | 966.95 Million USD | -477.005% |
| Edwards Lifesciences Corporation | -449.1 Million USD | 1342.351% |
| Paragon 28, Inc. | 36.39 Million USD | -15231.813% |
| Glaukos Corporation | 290.27 Million USD | -1822.135% |
| Globus Medical, Inc. | 53.11 Million USD | -10404.971% |
| Inspire Medical Systems, Inc. | -160.69 Million USD | 3572.13% |
| Integer Holdings Corporation | 1.01 Billion USD | -448.461% |
| Medtronic plc | 24.76 Billion USD | 77.469% |
| Nevro Corp. | 117.61 Million USD | -4643.984% |
| Owlet, Inc. | -1.34 Million USD | 416162.95% |
| Penumbra, Inc. | 66.85 Million USD | -8245.274% |
| Vicarious Surgical Inc. | -37.99 Million USD | 14786.496% |
| Smith & Nephew plc | 2.78 Billion USD | -100.554% |
| Sonendo, Inc. | 26.34 Million USD | -21080.624% |
| STERIS plc | 3.17 Billion USD | -75.666% |
| Stryker Corporation | 10.02 Billion USD | 44.34% |
| Vapotherm, Inc. | 102.66 Million USD | -5334.463% |